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Abstract 
To investigate the role and mechanism of catalpol in brain angiogenesis in a rat model of 
stroke, the effect of catalpol (5 mg/kg; i.p) or vehicle administered 24 hours after permanent 
middle cerebral artery occlusion (pMCAO) on behavior, angiogenesis, ultra-structural inte-
grity of brain capillary endothelial cells, and expression of EPO and VEGF were assessed. 
Repeated treatments with Catalpol reduced neurological deficits and significantly improved 
angiogenesis, while significantly increasing brain levels of EPO and VEGF without worsening 
BBB edema. These results suggested that catalpol might contribute to infarcted-brain angi-
ogenesis and ameliorate the edema of brain capillary endothelial cells (BCECs) by upregulating 
VEGF and EPO coordinately. 
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1. Introduction 
Stroke  has  been  emerging  as  one  of  the  most 
c o m m o n   c a u s e s   o f   m o r t a l i t y   a n d   m o r b i d i t y   i n   m o d e r n  
society. Although  much  progress  has  been  made  to-
ward understanding the mechanistic basis of stroke, 
the effectiveness of drugs available for stroke patients 
is limited. Tissue plasminogen activator (TPA), which 
dissolves blood clots in the brain, is presently the only 
approved treatment for stroke; however, it is effective 
o n l y   i n   t h e   f i r s t   3   h   a f t e r   t h e   s t r o k e   a n d   m a y   l e a d   t o  
cerebral  hemorrhage  [1].  Many  drugs  focus  on  the 
ischemic penumbra and cascade of damage, including 
anti-N-methyl-D-aspartate  receptor  (Aptiganel  and 
gavestinel),  potassium  channel  agonists  (MaxiPost), 
and GABA modulators (Zendra). However, the uses 
of  these  drugs  for  stroke  have been  abandoned  be-
cause  they  are  not  effective  and  even  harmful  to 
stroke patients, despite their apparent effectiveness in 
animal models of brain ischemia [2]. Therefore, new 
drugs  are  in  demand  and  need  to  be  developed  to 
treat stroke.  
The neurovascular unit concept emphasizes not 
o n l y   t h e   n e u r o n   b u t   a l s o   t h e   b r a i n   v a s c u l a r   s t r u c t u r e  
[3-4 ] .   P r e v i o u s   r e s e a r c h   o n   s t r o k e   h a s   l a r g e l y   f o c u s e d  
on neuroprotection, but neglected the ischemic vas-
cular  structure  and  the  possible  b e n e f i t s   o f   i t s   f u n c-
tional reconstruction [1,4,5]. Brain vascular structures 
are  coupled  with  brain  neurons  in  structure  and 
function [6]. Angiogenesis is associated with neuro-
genesis [7]. Mounting evidence has shown that vas-
cular-remodeling occurs after stroke [8-9 ] .   I t   h a s   b e e n  Int. J. Biol. Sci. 2010, 6 
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s h o w n   t h a t   h i g h e r   b l o o d   v e s s e l   c o u n t s   c o r r e l a t e   w i t h  
longer  survival  in  stroke  patients  [10].  The 
three-dimensional images of angiogenesis in the tis-
sue surrounding focal brain infarcts are demonstrated 
by scanning electron microscopy with corrosion cast-
i n g   [ 1 1 ] .   T h e s e   s t u d i e s   s u g g e s t   t h a t   t a r g e t i n g   b r a i n  
vascular-remodeling for drug discovery is necessary 
for stroke and even for ischemia disease. 
Rehmannia  Root  is  the  main  natural  herbal 
m e d i c i n e   t h a t   p l a y s   a n   i m p o r t a n t   r o l e   i n   t r e ating 
s t r o k e .   R e c e n t l y ,   c a t a l p o l ,   a   m a i n   a c t i v e   c o m p o n e n t   o f  
R e h m a n n i a   R o o t ,   w a s   d e t e r m i n e d   t o   p o s e extensive 
ischemic  neural  protection,  such  as  preventing  the 
l o s s   o f   h i p p o c a m p a l   C A 1   n e u r o n s   a n d   r e d u c i n g  
working  errors  [ 1 2 ] ,   m o d u l a t i n g   t h e   e x p r e s s i o n s   o f  
Bcl-2  and  Bax  [13],  attenuating  apoptosis  in  the 
ischemic  brain  [13],  and  increasing  hippocampal 
neuroplasticity by up-regulating PKC and BDNF in 
aged  rats  [14].  Catalpol  improves  Y-maze  perfor-
mance and the survival of neurons in the CA1 sub-
field after transient global ischemia in gerbils [15-16]. 
Our previous studies have demonstrated that catalpol 
a t   d o s e s   o f   1 0   a n d   5   m g / k g   c a n   i m p r o v e   n e u r o b e h a-
vioral  outcome  following  permanent  focal  cerebral 
ischemia in Sprague Dawley rats, and upregulate the 
expression of growth-associated protein 43 (GAP-43) 
[17]. These findings suggest that catalpol contributes 
to neuroplasticity after stoke. However, whether cat-
alpol  can  modulate  brain  angiogenesis  after  focal 
ischemia is unclear. 
Erythropoietin  (EPO)  and  Vascular  endothelial 
g r o w t h   f a c t o r   ( V E G F )   h a v e   p l e i o t r o p i c   e f f e c t s   o n   b r a i n  
function,  including  neuroprotection, and  promotion 
of angiogenesis and neurogenesis [18]. Notably, EPO 
enhances  angiogenesis,  without  aggravating  brain 
edema, even used with VEGF [19].  
In this study, we have investigated the effect of 
catalpol on angiogenesis following permanent middle 
cerebral artery occlusion (pMCAO) in rats. In order to 
explore  the  cellular  and  molecular  mechanism  by 
w h i c h   c a t a l p o l   m a y   r e g u l a t e   t h e   v a s c u l a r   p l a s t i c i t y   o f  
t h e   b r a i n ,   w e   e x a m i n e d   t h e   e x p r e s s i o n   o f   V E G F   a n d  
EPO by immunohistochemistry and western blotting. 
2. Materials and Methods 
2.1 Animals and diets  
Healthy  male  Sprague-Dawley (SD)  rats (220∼
280 g) were obtained from the Experimental Animal 
Center,  Chongqing  University  of  Medicine,  China. 
Animals  were  housed  under  conditions  of  natural 
illumination with food and water available ad libi-
tum.  These  experiments  were  performed  in  accor-
d a n c e   w i t h   C h i n a ’ s   g u i d e l i n e s   f o r   c a r e   a n d   u s e   o f   l a-
boratory animals. An i m a l s   w e r e   d i v i d e d   i n t o   3   g r o u p s  
r a n d o m l y   ( 1 )   t h e   s h a m   o p e r a t e d   g r o u p   ( n   =   2 4 ) ;   ( 2 )   t h e  
v e h i c l e   g r o u p   ( n   =   2 4 ) ;   ( 3 )   t h e   c a t a l p o l -treated group 
(n = 24). 
2.2 The pMCAO model 
Strokes  were  induced  by  electrocoagulation  of 
the  right  middle  cerebral  artery  as  described  pre-
viously  with  minor  modifications  [20].  Briefly,  rats 
were anesthetized and placed in a stereotaxic instru-
ment (Shanghai Jiangwan) in the prone position. The 
s c a l p   w a s   o p e n e d   a n d   b r a i n   w a s   e x p o s e d ,   h e l d   u p  
lightly  with a  glass  retractor,  inferior  cerebral  vein 
and olfactory bundle were seen perspicuously and the 
right middle cerebral artery was along the brain sur-
face verticality striding over inferior cerebral vein and 
olfactory bundle. The middle cerebral artery ventral 
to  the  olfactory  tract  was  electrocoagulated  (power 
35W), resulting in infarction of the right dorsolateral 
cerebral cortex. Rats were prescreened to select those 
in line with the criteria described as Bederson [21]. 
2.3 Drug administration  
Catalpol was dissolved in physiological saline, 
w h i c h   w a s   p u r c h a s e d   f r o m   N a t i o n a l   I n s t i t u t e   f o r   t h e  
Control  of  Pharmaceutical  and  Biological  Products 
( C h i n a )   a n d   i t s   p u r i t y   w a s   m o r e   t h a n   9 8 % .   C a t a l p o l  
(5mg/kg, ip) were administered 24h after stroke and 
then d a i l y   f o r   7   d a y s .   L i k e w i s e ,   t h e   s h am-operation 
g r o u p   a n d   t h e   v e h i c l e   g r o u p   r e c e i v e d   e q u a l   v o l u m e s  
of physiological saline by ip injection. The dose of 
c a t a l p o l   w a s   b a s e d   o n   o u r   p r e v i o u s   s t u d y   [ 1 7 ]   a n d  
Li’s study [15-16]. 
2.4 Bederson’s Score  
After operation, the neurological function of all 
animals was evaluated daily with a 4-point scale as 
previously described [21]: (0) no apparent deficit, (1) 
contralateral  forelimb  flexion,  (2)  lowered  resistance 
to  lateral  push  without  circling, and  (3)  circling  to 
ipsilateral stroke if spontaneous activity. 
2.5 Beam-Walking test 
Beam walking test [22-23] was used to evaluate 
sensorimotor reflexes, motor strength and coordina-
tion. The testing apparatus was a 2.5 cm in diameter 
a n d   8 0   c m   i n   l e n g t h   w o o d e n   b e a m   e l e v a t e d   1 0 0   c m  
a b o v e   t h e   f l o o r   w i t h   w o o d e n   supports as described by 
Stanley et al, and a 5cm thickness foam pillow placed 
under the beam avoid getting wound in a fall. 
R a t s   w e r e   a l l o w e d   t o   w a l k   t o   a   p l a t f o r m   l o c a t e d  
a t   t h e   e n d   o f   t h e   b e a m   a n d   t h e i r   b e h a v i o r s   w e r e   r e c-
orded based on the following six criteria: (0) the rat 
t r a v e r s e s   t h e   b e a m   w i t h o u t   f a l l i n g   d o w n ;   ( 1 )   t h e   r a t  
traverses the beam but footslips less than 50%; (2) the Int. J. Biol. Sci. 2010, 6 
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r a t   c r o s s e s   t h e   b e a m   b u t   f o o t s l i p s   m o r e   t h a n   5 0 % ;   ( 3 )  
t h e   r a t   c r o s s e s   t h e   b e a m   w i t h o u t   t h e   a i d   o f   t h e   a f f e c t e d  
hindlimb; (4) t h e   r a t   c a n ’ t   t r a v e r s e s   t h e   b e a m   b u t   c a n  
s i t   o n   t h e   h o r i z o n t a l   s u r f a c e   o f   t h e   b e a m ;   ( 5 )   t h e   r a t  
w i l l   f a l l   d o w n   w h e n   p l a c e d   o n   t h e   b e a m .   E a c h   t r i a l  
consisted of five repetitions of this assay. 
2.6 Examination of the healing Ischemic brain 
cortex and the surface vessels  
S t r o k e   m o d e l   r a t s   i n   e a c h   g r o u p   w e r e   s a c r i f i c e d  
1 5   d a y s   a f t e r   t h e   o p e r a t i o n .   A f t e r   r e m o v i n g   t h e   s u r-
face meninges, the surface vessels, distribution pat-
terns, and the healing state of ischemic cortex were 
examined  using  a  microscope  attached  to  a  digital 
camera as described previously [24]. 
2.7 Tissue preparation 
Fifteen  days  after  operation/stroke  induction, 
the rats were deeply anesthetized with an overdose of 
Chloral Hydrate (35 mg/mL, i.p), and transcardially 
p e r f u s e d   w i t h   0 . 9   %   N a C l   solution  to  rinse  out  the 
b l o o d ,   f o l l o w e d   b y   2 5 0   m L   o f   4 %   f o r m a l i n   ( 4 ° C )   t o   f i x  
t h e   b r a i n   t i s s u e .   A f t e r   e x t r a c t i o n   f r o m   t h e   s k u l l ,   t h e  
brains  were  post-fixed in 4% formalin solution and 
subsequently  cut  into  30  µm  coronal  sections  on  a 
cryostat  (Leica).  For  EPO  analyses,  imbedded  brain 
tissue was used. Ip s i l a t e r a l   i s c h e m i c   c o r t e x   ( 0 . 1   g   p e r  
b r a i n )   i n   e a c h   g r o u p   w a s   a l s o   w e i g h e d   f o r   w e s t e r n 
blotting analyses.  
2.8 Immunohistochemistry  
Animal  brain  tissues  were  transcardially  per-
fused and fixed with 4% paraformaldehyde, cryopre-
served  in  30%  sucrose,  and  cut  into  three  series  of 
consecutive sections (30   μ m )   a t   a   C r y o s t a t .   E a c h   s e t   o f  
tissue sections was immunostained for PCNA,  VWF 
or VEGF. For  EPO  analyses, imbedded  brain  tissue 
was used to  cut  as  5μm  sections. For  immunohisto-
chemistry, tissue sections were incubated with rabbit 
polyclonal antibody against EPO  (1:200, santa cruz, 
USA),  VEGF(1:200,  Wuhan  Booster  Biotech.  Co., 
China).  For  double-fluorescence  labeling,  cross  sec-
tions were incubated with the vessel   m a r k e r   a n t i b o d y ,  
rabbit  polyclonal  against  VWF  (1:200,  Zhongshan 
B i o t e c h .   C o . ,   C h i n a ) ,   t o g e t h e r   w i t h   t h e   m o u s e   m o-
noclonal  antibody  against  the  proliferation  marker 
PCNA  (1:200,  Wuhan  Booster  Biotech.  Co.,  China). 
Immunohistochemistry  for  EPO w a s   d o n e   w i t h  bio-
tinylated  goat  anti-rabbit IgG (1:500; Vector Labora-
tories) and peroxidase-conjugated avidin-biotin com-
plex (ABC kit; Wuhan Booster Biotech. Co., China), 
bound antibodies were visualized by addition of di-
aminobenzidine. VEGF  sections then incubated with 
Cy3-labeled goat anti-r a b b i t   I g G   ( W u h a n   B o s t e r   B i o-
tech.  Co.,  China).  PCNA  and  VWF  then  incubated 
with Cy3-labeled goat anti-rabbit IgG (Wuhan Boster 
Biotech.  Co.,  China)  and  FITC-labeled  goat  an-
ti-m o u s e   I g G . After through washing, immunostained 
cells  wer e   o b s e r v e d   u n d e r   a   N i k o n   m i c r o s c o p e   a n d  
w e r e   d o c u m e n t e d   w i t h   a   N i k o n   d i g i t a l   c a m e r a .   I m-
munofluorescence  staining  for  PCNA  (green)  and 
VWF (red) or VEGF ( r e d )   w a s   v i s u a l i z e d   a n d   d o c u-
m e n t e d   w i t h   a   c o n f o c a l   m i c r o s c o p e  (Leica). According 
to  Acker  [25]  (Acker  et  al.,  2001),  the  number  of 
double-stained  vessels  and  the  intensity  of  staining 
were  analyzed  with  Image  Pro  Plus  Version  6.0. 
software  for  cerebral  microvessels  at  the  boundary 
zone of ischemia. Five f i e l d s   o f   e a c h   s l i c e   w e r e   r a n-
domly selected for blinded scoring and analyses. Each 
experiment was performed three times. 
2.9 Electron microscopy observation of brain 
vascular endothelial cells  
R a t s   i n   e a c h   g r o u p   w e r e   a n e s t h e t i z e d   w i t h   3 . 5 %  
c h l o r a l   h y d r a t e   ( 3 5   m g / m L ,   i . p )   a n d   p e r f u s e d   f o r   2 -3 
min  thro u g h   t h e   a s c e n d i n g   a o r t a   w i t h   0 . 9 %   n o r m a l  
saline, followed by ice-cold fixative (4% paraformal-
d e h y d e   i n   0 . 1   M   P B S   f o r   3 0   m i n ) .   T h e   b r a i n s   w e r e  
removed  for  immunocytochemical  electron  micro-
scopic studies and fixed in 4% paraformaldehyde in 
0 . 1   M   P B S   p H   7 . 4   f o r   3 ～4   h   a t   4 ° C .   T h e   b r a i n   w a s   t h e n  
r i n s e d   i n   P B S   f o r   3 0   m i n ,   t r e a t e d   w i t h   1 %   O s O 4 for 30 
min, dehydrated in sequential ethanol gradients, and 
embedded  in  Epon  618.  Ultrathin  sections  were 
processed  according  to  the  postembedding  proce-
dure.  Briefly,  ultram i c r o c u t   w a s   m a d e   b y   L e i c a   u l-
tramicrotome to collect 60nm-thick sections. The sec-
t i o n s   w e r e   m o u n t e d   o n   f o r m v a r -coated copper grids, 
incubated in uranyl acetate- acetate lead double elec-
t r o n   s t a i n ,   a n d   o b s e r v e d   f o r   b r a i n   v a s c u l a r   e n d o t h e l i a l  
cells.  
2.10 Western blotting  
According  to  K.N.  Nam  [26]  and  Cao  Huang 
[27], brain cortex in peri-ischemic were lysed on ice in 
lysis buffer [50 mm  Tris-HCl (pH 8.2), 0.5 M saccha-
rose, 10 mMHEPES (pH 7.9), 1.5 mM MgCl2, 10 mM 
K C l ,   1   m M   E D T A ,   1 0 %   ( v / v )   g l y c e r i n e ,   1   m M   D TT, 1 
mM PMSF, 10μg/mL Aprotinin, and 5μg/mL Leu-
peptin]. After centrifugation at 16,000 ×g for 10 mi-
nutes.  Protein  content  in  cleared  lysate  was  deter-
mined by Bradford Assay. Lysate samples containing 
40μg  of  protein were  fractionated  by  SDS-10%  po-
lyacrylamide  gel  electrophoresis  and  then  electrob-
lotted onto PCVF  membranes. The membranes were 
probed with primary antibodies as EPO, VEGF (1:250, 
1:300, Satcruze Co., USA),  and  β-actin(1:200, Booster 
Biotech. Co., Wuhan, China), then incubated with the 
horseradish  peroxidase-conjugated  goat  anti-mouse Int. J. Biol. Sci. 2010, 6 
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or anti-rabbit I g G   ( 1 : 2 5 0 0 ;   B o o s t e r   B i o t e c h .   C o . ,   W u-
han, China), t h e   P V D F   m e m b r a n e   w a s   p u t   i n t o   D A B  
fluid  for  coloration.  Immunoreactivity  was  digitally 
scanned by ScanMaker E6 system and  quantified us-
ing Quantity one 4.5.1 (Bio-Rad) software. β-actin was 
used as an internal control for all Western blotting. 
2.11 Image and data analysis 
After  capturing  images  with  a  digital  camera, 
quantification  of  the  results  from  immunohistoche-
mistry,  immunofluorescence,  western  blotting  was 
performed with Image Pro Plus Version 6.0. software. 
EPO or VEGF-positive cells were counted a t   f i v e   d i f-
ferent fields in the inner border of the peri-ischemic 
cortex in five sections per rat, the total number of EPO 
o r   V E G F -positive cells per image (cells/cm 2,   o b j e c t i v e  
× 20 )   w a s   c a l c u l a t e d   b y   a n   o b s e r v e r   b l i n d   t o   t h e   e x-
perimental  treatment.  In  each  section,  five  pe-
ri-ischemia  cortical  areas  outside  labeled  neurons 
were chosen randomly to obtain an average value for 
the subtraction of background by an observer blind to 
the experimental treatment.  
2.12 Statistical analyses 
Data were expressed as mean ± S.E.M. All data 
were  analyzed  by  one-way  analysis  of  variance 
(ANOVA) using SPSS 11.0 software. A value of p < 
0.05 was considered statistically significant.  
3. Results  
3.1 Catalpol improve sensorimotor performance 
in stroke rats  
 Post-stroke  administration  of  catapol  reduced 
Bederson's score in rats, indicating improved motor 
function  relative  to  vehicle  control,  catapol  signifi-
cantly reduced Bederson's scores in rats at 7 and 15 
days after stroke (Fig. 1A).  
The  Beam  walking  test  was  used  to  measure 
sensorimotor  function.  D u r i n g   t h e   c o u r s e   o f   t r e a t-
ment, beam walking scores were reduced; by day 15 
following stroke, score reductions in catapol-treated 
versus vehicle-treated animals reached statistical sig-
nificance (P<0.05) (Fig. 1B).  
 
Figure 1. Effects of intraperitoneal injection with catalpol on sensorimotor performance in post-surgical 
rats at days 1, 4 ,   7   a n d   1 5 . (A) Post-stroke treatment with catalpol reduced Bederson’s score in stroke rats and (B) 
decreased beam working score in stroke rats.   T h e   d a t a   a r e   p r e s e n t e d   a s   m e a n   ± SE. * p<0.05 compared with vehicle group, 
#p<0.01 compared with sham operation group. Int. J. Biol. Sci. 2010, 6 
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3.2 Effect of catalpol on the vascular pattern of 
the cerebral cortex surface 
T h e   e f f e c t   o f   c a t a l p o l   o n   t h e   v a s c u l a r   p a t t e r n   o f  
the rat cerebral cortex surface was examined follow-
ing pMCAO. In vehicle-treated  animals,  liquefactive 
n e c r o s i s   o f   t h e   b r a i n   w a s   o b s e r v e d   1 5   d a y s   a f t e r  
pMCAO.  Brains  from  vehicle-treated  animals  exhi-
bited  a  few  deranged  microvessels  (Figure  2A).  By 
c o n t r a s t ,   t h e   f o c u s   o f   c e r e b r a l   i s c h e m i a   w a s   n e a r  
normal in catalpol-treated animals; the brains of these 
animals exhibited more branched vessels crossing and 
gathering radially to the surface of cerebral ischemia. 
A l l   t h e s e   v e s s e l s   a r b o r i z e d   t o   f o r m   a   c o n t i n u o u s   n e t-
work of small blood vessels (Figure 2B). 
 
 
 
Figure  2. The  v a s c u l a r   p a t t e r n   i n   c e r e b r a l   c o r t i c a l   s u r f a c e   i n   r a t s   1 5   d a y s   a f t e r   p M C A O .  (A) In the ve-
hicle-treated group, the pale brain surface had few vessel branch points, infarct areas were characterized by liquefactive 
necrosis, cortical surface vessels were scarce and rearranged, several discontinued vascular structures were observed, and 
the radial patterns were lost. (B) In the catalpol-treated group, brain surface vessel branch points increased obviously, 
vascular structures continued, focus on the infarct area was present, and the vessel radial patterns and brain tissue infarct 
area were close to normal. Arrow points to vascular structures around the ischemia area. 
 
3.3 Catalpol enhanced brain angiogenesis in the 
peri-infarcted area of the cortex  
The effect of catalpol on angiogenesis was then 
examined  by  immunostaining   o f   b r a i n   s e c t i o n s   f o r  
von Willebrand Factor (vWF), a marker of endothelial 
cells,  and  for  proliferating  cell  nuclear  antigen 
(PCNA),  a  marker  of  cell  proliferation.  VWF  and 
PCNA  co-localization  points  in  the  sham  operation 
group were scarcly observed (Fig 3A).Compared with 
the  vehicle-treated  group  (34  ±  3.25)  (Fig  3B),  the 
number of VWF and PCNA co-localization points in 
the  catalpol-treated group (Fig 3C and  D) increased 
significantly  (p  <  0.05).  The  number  of  vWF  and 
PCNA  co-localization  points  in  the  catalpol-treated 
group  (Fig  3C  and D) was 233.67 ± 89.51, nearly 6 
t i m e s   t h a t   i n   t h e   v e h i c l e   g r o u p   ( p < 0.01) (Fig 3B and 
D).  These  results  also  agreed  with  results  obtained 
from  integral  optical  density  (IOD)  analyses  in  the 
vWF-PCNA  co-localization area (Fig 3E). These data 
demonstrate that catalpol plays an important role in 
cerebral ischemia angiogenesis.  
3.4 Effects of catalpol on brain capillary endo-
thelial cells (BCECs) 
T h e   i n f l u e n c e   o f   c a t a p o l   t r e a t m e n t   o n   B C E C   m i-
crostructure  following  pMCAO  were  examined  by 
transmission  electron  microscopy.  Compared  to  ve-
hicle cotntrol (Fig 4A), catalpol significantly reduced 
BCEC edema (Fig 4B). The number of chondriosomes 
in the catalpol-treated group was higher than that in 
the vehicle group and close to normal levels. 
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Figure 3. Angiogenesis surrounding ischemic cortical area as demonstrated by immunocytochemistry and 
laser scanning confocal microscopy. The effects of Catalpol on angiogenesis were indicated by double-staining for 
V W F ,   a   m a r k e r   o f   e n d o t h e l i a l   c e l l s   a n d   f o r   p r o l i f e r ating cell nuclear antigen (PCNA), a marker of cell proliferation. 
Co-labeling of PCNA (green) and VWF (red) demonstrates angiogenesis, i.e., endothelial proliferation in the capillaries, in 
the peri-i n f a r c t e d   a r e a   a t   1 5   d a y s   a f t e r   p M C A O .   C o -localization of   P C N A   a n d   V W F   i s   y e l l o w .  ( A )   S h a m   o p e r a t i o n   g r o u p ,   ( B )  
Vehicle-treated group, (C) Catalpol-t r e a t e d   g r o u p .   B a r s   =   1 5 0   μm   i n   A ,   B ,   a n d   C .   T h i s   a n a l y s i s   d e m o n s t r a t e d that few vessels 
were double-s t a i n e d   b y   V W F   a n d   P C N A   i n   s h a m -operated rats (A), but significa n t   r e m o d e l i n g   o f   t h e   m i c r o v e s s e l   n e t w o r k  
o c c u r r e d   i n   t h e   i n f a r c t e d   h e m i s p h e r e   a n d   t h e   n u m b e r   o f   v e s s e l s   w i t h   s m a l l   d i a m e t e r   a n d   s h o r t   s e g m e n t   i n c r e a s e d   a t   1 5   d a y s  
after the stroke. More vessels were double-s t a i n e d   f o r   V W F   a n d   P C N A   i n   c a t a l p o l -treated group (C). Statistical analyses are 
s h o w n   i n   t h e   g r a p h   o f   t h e   n u m b e r   o f   v e s s e l s   c o - l a b e l e d   f o r   P C N A   a n d   V W F   ( D ) .   T h e   r e s u l t s   a b o v e   a g r e e d   w i t h   t h e   r e s u l t s  
of IOD analyses in the co-localization area (E). (
*P < 0.01). Int. J. Biol. Sci. 2010, 6 
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Figure 4 Ultrastructural observations of brain capillary endothelial cells (BCECs). In the vehicle-treated group 
( A ) ,   B C E C   e d e m a ,   c h r o m a t i n   r a r e f a c t i o n   ( s h o r t   a r r o w ) ,   a n d   c h o n d r i o s o m e   s w e l l i n g   ( l o n g   a r r o w )   w e r e   o b s e r v e d .   ( B )   I n   t h e  
catalpol group, BCECs, pykno-chromatin (short arrow), and chondriosome number and shape (long arrow) were close to 
normal or near normal. Bars = 1μm. 
 
3.5 Catalpol upregulated EPO and VEGF ex-
pression in rat brain following pMCAO 
To monitor the influence of catapol on EPO and 
VEGF expression, we performed immunohistochem-
ical analyses of brain sections derived from rats fol-
lowing pMCAO. EPO and VEGF- positive cells were 
detected  in  the  cell  membrane  and  cytoplasm.  Few 
EPO  positive  cells  were  observed  in  brain  sections 
derived  from  sham-treated animals  (Fig  5A).  Com-
pared  to  vehicle-treated animals (Fig 5B) ,   b r a i n   s e c-
tions derived from catapol-treated animals exhibited 
significantly increased EPO expression (Fig 5C). Sta-
tistical analyses revealed 7.2 ± 1.40 positive cell/cm2 
vs 15.3 ± 2 positive cell/cm2 in vehicle-treated versus 
catapol-treated animals (p< 0.05). Similar results were 
obtained by western blot analyses (Fig 5G and I); As 
for  VEGF,  immunofluorescence  analyses  demon-
strated  that  catalpol a t   t h e   d o s e   o f   5 m g /  kg signifi-
cantly upregulated VEGF expression compared with 
the  vehicle  group;  the  number of positive cell/cm2 
vehicle-treated versus catapol-treated animals was 8± 
1.6 vs 17 ± 2.5;  (p <  0.01) (Fig.  5E,F,H). Once  again, 
similar results were obtained by western blot analyses 
(Fig 5G and I). Statistical analyses were shown in Fig 
5I. 
4. Discussion  
There are three principal findings emerged from 
the  present  study.  Firstly,  catalpol  treatment  im-
proved  neurofunction  after  stroke,  as  evidenced  by 
e n h a n c e d   s c o r e s   i n   t h e   b e a m   w a l k i n g test designed to 
evaluate  sensorimotor  reflexes,  motor  strength  and 
coordination. Secondly, our results show that catapol 
enhances brain angiogenesis following stroke without 
worsening  stroke  brain  edema.  Finally,  we  demon-
strate  that  the  ameliorative  effects  of  catalpol  on 
stroke brain are mediated by enhanced expression of 
EPO and VEGF.   O u r   f i n d i n g s   t h u s   p r o v i d e   n e w   i n-
sights into the likely regulatory mechanisms of cata-
pol. 
Ischemic stroke is a serious disease caused by a 
thrombus (blood clot), which can result in permanent 
neurological damage, complications, and even death 
[26].The  standard method  of treatment is to dissolve 
the clot and restore blood flow in the blocked vessel. 
The drug TPA is approved for this use; however, TPA 
is used only 3-6 hours after stroke, and  the more ra-
p i d l y   b l o o d   f l o w   i s   r e s t o r e d   t o   t h e   b r a i n ,   t h e   f e w e r  
brain cells die [27]. Recent research has suggested that 
a n   a l t e r n a t i v e   a p p r o a c h   t o   r e s t o r e   b l o o d   f l o w   i s   t o  
promote  angiogenesis  in  regions  surrounding  the 
ischemic brain.  
As  one  of  the  most  potentangiogenic  factors, 
V E G F   i s   u p -regulated by focal cerebral ischemia not 
only  i n   a n i m a l   m o d e l s   b u t   a l s o   i n   h u m a n   p a t i e n t s  
[10-11]  as  an  angiogenic,  neurotrophic,  and  neuro-
protective factor [28-30].   V E G F   a l s o   p l a y s   a   v i t a l   r o l e  
during neural [29,31] and vascular remodeling [32-33] 
after  stroke.  Our  results  showed  that  ischemia  in-
duced VEGF expression, which was not enough for 
vascular remodeling, but catalpol treatment increased 
VEGF expression together with increased microvessel 
formation,  healed  the  ischemic brain, and improved 
neurobehavioral score. These data suggested that cat-
alpol  stimulated  brain  angiogenesis  after  stroke  by 
increasing the secretion of endogenous VEGF. Int. J. Biol. Sci. 2010, 6 
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Figure 5 Catalpol upregulated EPO and VEGF expression in pMCAO rat brains. Immunohistochemistry results 
showing neurons with EPO (A, B, C,   2 0 0 × )   a n d   V E G F   ( D, E, F, 200×) in the peri-infarcted area of a pMCAO rat, a 
sham-operated rat (A & D), a vehicle-treated rat (B & E), and a catalpol-treated rat (C & F). EPO and VEGF expression 
detected by western blot showed in (G). The internal control was β-actin. Vs vehicle group 
*p < 0.05. The experiments 
repeated three times and 6 rats used in each group. Statistical bars shown as H and I respectively. Int. J. Biol. Sci. 2010, 6 
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Moreover, VEGF, known as vascular permeabil-
ity  factor,  is  associated with  angiogenesis,  vascular 
permeability  and  neuroprotection.  VEGF  enhances 
a n g i o g e n e s i s ,   b u t   w o r s e n s   r a t h e r   t h a n   i m p r o v e s   c e-
rebral haemodynamics after stroke [34-35]. Low-dose 
VEGF  aggravates  hemorrhagic  transformation  [36]. 
Inhibition of endogenous VEGF by topical application 
of  anti-VEGF  antibody  in  the  ischemic  cortex  de-
creased the blood-brain barrier (BBB) disruption [37]. 
VEGF is in part  responsible  for  the BBB  disruption 
during the early stage of focal cerebral ischemia [37]. 
These adverse effects suggested that  caution  should 
be heeded when considering the use of only VEGF for 
stroke patients [38]. 
E P O   i s   a   p l e i o t r o p i c   f a c t o r  [39]. EPO and  EPO 
receptor (EPO-R) are expressed in neurons, astrocytes, 
and endothelial cells after focal permanent ischemia 
in mice. EPO is a neuroprotective factor [40-41], which 
improves functional recovery and reduces neuronal 
apoptosis [42] and inflammation [43]. EPO h a s   a   m i-
togenic and positive chemotactic effect on endothelial 
cells  and  endothelial  progenitor  cells  [44-45].  It  sti-
mulates  angiogenesis  in  vitro  and  in  vivo  [18,40]. 
Therefore,  the  EPO/EPO-R  system  is implicated in 
the process of neuroprotection [46] and restructuring 
(such as angiogenesis) after ischemia [18,46]. In this 
study, catalpol increased EPO expression in neurons 
and  endothelial-like  cells  surrounding  the  vessels. 
Therefore, catalpol may improve neurofunction and 
neural and vascular remodeling after stroke by acti-
vating EPO. 
I n   t h i s   s t u d y ,   w e   observed  that  catalpol  in-
creased V E G F   e x p r e s s i o n   b u t   d i d   n o t   i n c r e a s e   v a s c u-
lar permeability (Fig 3b), which m a y   b e   r e l a t e d   t o   t h e  
simultaneous increase of EPO expression in the brain. 
EPO reduces the side effects of VEGF, which protects 
the BBB against VEGF-induced permeability in vitro 
[19].  EPO  a n d   V E G F   p r o m o t e   n e u r a l   o u t g r o w t h  
(Bocker-Meffert et al., 2002) and exhibit equal angi-
ogenic  potential [18]. Furthermore VEGF modulates 
erythropoiesis  through  regulation  of  adult  hepatic 
erythropoietin  synthesis  [47],  and  EPO-R  promotes 
VEGF  expression  and  angiogenesis  in  peripheral 
ischemia  in  mice  [48].  Therefore,  the  advantageous 
reciprocal  interactions  between  EPO  and  VEGF  on 
a n g i o g e n e s i s ,   w h i c h   c a n   b e   i n d u c e d   b y   c a t a p o l   m a y  
b e   a n   e f f e c t i v e   w a y   t o   t r e a t   s t r o k e   p a t i e n t s .   B r a i n   i n-
jury  helps  EPO to   c r o s s   t h e   B B B  [49-50], which  may 
then produce a synergistic effect with VEGF. Catalpol 
is  the  effective  component  of  Rehmannia  glutinosa, 
which  can  increase  blood  level  of  E P O   ( d a t a   n o t  
shown). Moreover, catapol can cross the BBB, as de-
tected by HPLC even in normal rats [51]. 
In conclusion, our data suggested that  catalpol 
modulated angiogenesis through increased EPO and 
V E G F   a f t e r   s t r o k e ,   w h i c h   m a y   b e   t h e   m e c h a n i s m   b y  
which  catalpol  reduced  ischemic  neuronal  damage 
and  enhanced  functional  recovery.  Taken  together, 
these data suggested t h a t   c a t a l p o l   m a y   i m p r o v e   c o l-
lateral circulation and provide impact o n   s t r o k e   p a-
tients  through  new  blood  vessel  formation.  Future 
r e s e a r c h   m a y   e l u c i d a t e   t h e   s p e c i f i c   s i g n a l i n g   p a t h-
ways through which catalpol increases angiogenesis. 
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